The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Glofitamab in R/R NHL: How does step-up dosing compare with fixed dosing?
Featured:
Carmelo Carlo-StellaDuring the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Carmelo Carlo-Stella, Humanitas University, Milan, IT. We asked, How does step-up dosing compare with fixed dosing for glofitamab in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)?
Glofitamab in R/R NHL: How does step-up dosing compare with fixed dosing?
Glofitamab is an anti-CD20 and anti-CD3 bispecific antibody investigated for use in R/R NHL. Carlo-Stella provides updated efficacy data from an ongoing phase I trial observing the effect of dose escalation of glofitamab on overall response and complete metabolic response.